FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955141834> ?p ?o ?g. }

• W2955141834 endingPage "930" @default.
• W2955141834 startingPage "930" @default.
• W2955141834 abstract "Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer histotype, characterized by high biological aggressiveness and scarce treatment options. Recently, we have established a clinically relevant murine HCC model by co-expressing activated forms of v-akt murine thymoma viral oncogene homolog (AKT) and oncogene c-mesenchymal-epithelial transition (c-Met) proto-oncogenes in the mouse liver via hydrodynamic tail vein injection (AKT/c-MET mice). Tumor cells from these mice demonstrated high activity of the AKT/ mammalian target of rapamycin (mTOR) and Ras/ Mitogen-activated protein kinase (MAPK) signaling cascades, two pathways frequently co-induced in human HCC. Methods: Here, we investigated the therapeutic efficacy of sorafenib, regorafenib, the MEK inhibitor PD901 as well as the pan-mTOR inhibitor MLN0128 in the AKT/c-Met preclinical HCC model. Results: In these mice, neither sorafenib nor regorafenib demonstrated any efficacy. In contrast, administration of PD901 inhibited cell cycle progression of HCC cells in vitro. Combined PD901 and MLN0128 administration resulted in a pronounced growth constraint of HCC cell lines. In vivo, treatment with PD901 or MLN0128 alone moderately slowed HCC growth in AKT/c-MET mice. Importantly, the simultaneous administration of the two drugs led to a stable disease with limited tumor progression in mice. Mechanistically, combined mitogen-activated extracellular signal-regulated kinase (MEK) and mTOR inhibition resulted in a stronger cell cycle inhibition and growth arrest both in vitro and in vivo. Conclusions: Our study indicates that combination of MEK and mTOR inhibitors might represent an effective therapeutic approach against human HCC." @default.
• W2955141834 created "2019-07-12" @default.
• W2955141834 creator A5007592619 @default.
• W2955141834 creator A5014493738 @default.
• W2955141834 creator A5022582588 @default.
• W2955141834 creator A5028462736 @default.
• W2955141834 creator A5031681400 @default.
• W2955141834 creator A5037736282 @default.
• W2955141834 creator A5038202726 @default.
• W2955141834 creator A5040373155 @default.
• W2955141834 creator A5044544424 @default.
• W2955141834 creator A5046126034 @default.
• W2955141834 creator A5052102629 @default.
• W2955141834 creator A5062134753 @default.
• W2955141834 creator A5073501391 @default.
• W2955141834 creator A5079781095 @default.
• W2955141834 creator A5091038323 @default.
• W2955141834 date "2019-07-03" @default.
• W2955141834 modified "2023-09-27" @default.
• W2955141834 title "Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma" @default.
• W2955141834 cites W1592490241 @default.
• W2955141834 cites W1888543545 @default.
• W2955141834 cites W1971837077 @default.
• W2955141834 cites W1974058738 @default.
• W2955141834 cites W1977267072 @default.
• W2955141834 cites W1994193851 @default.
• W2955141834 cites W2016450639 @default.
• W2955141834 cites W2018992554 @default.
• W2955141834 cites W2050512142 @default.
• W2955141834 cites W2052326711 @default.
• W2955141834 cites W2055254495 @default.
• W2955141834 cites W2057272791 @default.
• W2955141834 cites W2065455574 @default.
• W2955141834 cites W2067224679 @default.
• W2955141834 cites W2069421644 @default.
• W2955141834 cites W2070396671 @default.
• W2955141834 cites W2080219242 @default.
• W2955141834 cites W2087106096 @default.
• W2955141834 cites W2108441134 @default.
• W2955141834 cites W2117933729 @default.
• W2955141834 cites W2132052921 @default.
• W2955141834 cites W2136390065 @default.
• W2955141834 cites W2161299239 @default.
• W2955141834 cites W2162242700 @default.
• W2955141834 cites W2170834007 @default.
• W2955141834 cites W2286842342 @default.
• W2955141834 cites W2294090452 @default.
• W2955141834 cites W2324407602 @default.
• W2955141834 cites W2409945629 @default.
• W2955141834 cites W2480694468 @default.
• W2955141834 cites W2505837069 @default.
• W2955141834 cites W2560499218 @default.
• W2955141834 cites W2593816418 @default.
• W2955141834 cites W2737501041 @default.
• W2955141834 cites W2791698913 @default.
• W2955141834 cites W2793191983 @default.
• W2955141834 cites W2794466912 @default.
• W2955141834 cites W2803195783 @default.
• W2955141834 cites W2827674523 @default.
• W2955141834 cites W2883204623 @default.
• W2955141834 cites W2892054361 @default.
• W2955141834 cites W2896869836 @default.
• W2955141834 cites W2907163314 @default.
• W2955141834 cites W2917837889 @default.
• W2955141834 cites W2926997511 @default.
• W2955141834 cites W4231112874 @default.
• W2955141834 cites W4236438320 @default.
• W2955141834 doi "https://doi.org/10.3390/cancers11070930" @default.
• W2955141834 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6679026" @default.
• W2955141834 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31277283" @default.
• W2955141834 hasPublicationYear "2019" @default.
• W2955141834 type Work @default.
• W2955141834 sameAs 2955141834 @default.
• W2955141834 citedByCount "8" @default.
• W2955141834 countsByYear W29551418342019 @default.
• W2955141834 countsByYear W29551418342020 @default.
• W2955141834 countsByYear W29551418342021 @default.
• W2955141834 countsByYear W29551418342022 @default.
• W2955141834 crossrefType "journal-article" @default.
• W2955141834 hasAuthorship W2955141834A5007592619 @default.
• W2955141834 hasAuthorship W2955141834A5014493738 @default.
• W2955141834 hasAuthorship W2955141834A5022582588 @default.
• W2955141834 hasAuthorship W2955141834A5028462736 @default.
• W2955141834 hasAuthorship W2955141834A5031681400 @default.
• W2955141834 hasAuthorship W2955141834A5037736282 @default.
• W2955141834 hasAuthorship W2955141834A5038202726 @default.
• W2955141834 hasAuthorship W2955141834A5040373155 @default.
• W2955141834 hasAuthorship W2955141834A5044544424 @default.
• W2955141834 hasAuthorship W2955141834A5046126034 @default.
• W2955141834 hasAuthorship W2955141834A5052102629 @default.
• W2955141834 hasAuthorship W2955141834A5062134753 @default.
• W2955141834 hasAuthorship W2955141834A5073501391 @default.
• W2955141834 hasAuthorship W2955141834A5079781095 @default.
• W2955141834 hasAuthorship W2955141834A5091038323 @default.
• W2955141834 hasBestOaLocation W29551418341 @default.
• W2955141834 hasConcept C121608353 @default.
• W2955141834 hasConcept C126322002 @default.
• W2955141834 hasConcept C150903083 @default.

• next